Compare ABCL & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABCL | XENE |
|---|---|---|
| Founded | 2012 | 1996 |
| Country | Canada | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.7B |
| IPO Year | 2020 | 2014 |
| Metric | ABCL | XENE |
|---|---|---|
| Price | $13.27 | $37.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 19 |
| Target Price | $16.70 | ★ $74.31 |
| AVG Volume (30 Days) | ★ 4.4M | 2.5M |
| Earning Date | 11-09-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 10.91 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $75,128,000.00 | $311,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.91 | $2,045.70 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 160.56 | N/A |
| 52 Week Low | $2.75 | $36.07 |
| 52 Week High | $14.98 | $72.66 |
| Indicator | ABCL | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 59.09 | 23.30 |
| Support Level | $10.38 | N/A |
| Resistance Level | N/A | $45.18 |
| Average True Range (ATR) | 0.77 | 1.94 |
| MACD | 0.05 | -0.55 |
| Stochastic Oscillator | 58.85 | 4.85 |
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.